The therapeutic application of Фосфокреатин (Phosphocreatine Disodium) is centered on providing crucial supportive relief to the heart during times of acute or disruptive episodes.

This treatment is relevant for conditions associated with acute or disruptive episodes, such as acute myocardial ischemia and infarction, and chronic heart failure. It is also commonly used during high-stress clinical settings involving major cardiac procedures.

“The primary benefit is centered on supporting the heart muscle through periods of heightened physiological stress, aiming to ease the overall symptom burden.”

The primary therapeutic focus helps support the heart muscle, and may assist with maintaining functional stability during a crisis. It is relevant for easing symptoms related to impaired cardiac pumping and electrical instability, contributing to easing the overall symptom load of functional decline in patients.

Regulatory References

1. NIH Medical Subject Headings

Eligibility Profile: Who Can and Cannot Use Фосфокреатин

The eligibility for using Фосфокреатин (Phosphocreatine Disodium injection) is strictly defined by regulatory documents, focusing on patient safety based on age, physiological status, and underlying comorbidities.

Contraindications (Must Not Use)

Populations Requiring Restriction

The official regulatory interaction profile for Phosphocreatine Disodium (Фосфокреатин) is defined by a notable absence of specific, formally documented interaction warnings or restrictions across authoritative government regulatory sources, such as the European Summary of Product Characteristics (SmPC). As an endogenous metabolite administered via injection, the substance typically bypasses the complex metabolic and transport pathways that often lead to drug-drug interactions.

Official Interaction Statements:

Regulatory documents do not list any specific medicinal products or substance classes as formally contraindicated for co-administration. The official prescribing information also does not report any pharmacokinetic interactions, such as those mediated by CYP450 enzymes or drug transporters, which would alter the exposure (e.g., clearance or AUC) of Phosphocreatine or co-administered drugs. Furthermore, due to the intravenous route of administration, the labels contain no documented statements regarding interactions with food, alcohol, or herbal supplements.

Connection to the overall interaction profile: The current regulatory structure establishes that no formal restrictions, prohibitions, or mandatory timing requirements are necessary for co-administration. This status reflects the compound's nature as a supportive bioenergetic substrate, which largely avoids typical complex drug interaction mechanisms requiring specific clinical management.

The mechanism of action of Фосфокреатин (Phosphocreatine, PCr) is central to cellular bioenergetics, primarily within high-demand tissues like the myocardium and skeletal muscle. It functions as a high-energy phosphate reservoir that interacts directly with the enzyme Creatine Kinase (CK). During periods of elevated metabolic activity or oxygen scarcity, the CK reaction utilizes PCr to rapidly transfer a phosphate group to ADP, thereby regenerating ATP, the cell's energy substrate. This immediate buffering activity influences the intracellular ATP concentration and the ATP/ADP ratio. PCr is also integral to the Creatine-Phosphate Shuttle, acting as a carrier molecule that facilitates the intracellular transport and compartmentalization of high-energy phosphate groups. This shuttle links the sites of ATP synthesis in the mitochondria with the sites of ATP consumption in the cytosol. By influencing these key pathways, the compound modulates cellular energy homeostasis, which is required for the continuous function of energy-dependent processes such as ion transport across membranes and myofibril activity.

How Фосфокреатин is Used: Official Administration Guidelines

Фосфокреатин (Phosphocreatine Disodium) is administered under strict clinical supervision due to its use as an acute cardioprotective agent, classified under the official ATC Code C01EB06. The medication is consistently supplied as a sterile powder for solution for injection/infusion, which mandates a specific method of preparation and delivery.

The only approved route of administration is parenteral, primarily through intravenous (IV) infusion or sometimes a slow IV bolus. This route is necessary to achieve rapid, systemic availability required in critical care settings. As a lyophilized powder, the product must be reconstituted with an appropriate sterile solvent, such as Water for Injection or 0.9% Sodium Chloride, immediately before use.

Administration follows a distinct short-term, two-phase regimen. The protocol typically begins with a higher initial loading dose to quickly establish the required concentration, followed by a reduced maintenance dose given once or twice daily (b.i.d.) for the remainder of the short course. Due to the need for controlled delivery, the IV solution is often required to be infused slowly over a specified duration (e.g., 30–60 minutes) to prevent issues associated with rapid administration.

Use of the drug is strictly confined to supervised medical environments, such as hospitals or intensive care units. Specific dose adjustments for populations like those with renal impairment may be required, which underscores the complexity of its usage and administration requirements.

Research Evidence / Overview of Studies for Фосфокреатин

Evidence for Use in High-Stress Cardiac Procedures

Фосфокреатин was widely evaluated in research focused on conditions associated with acute or disruptive episodes where the heart is subjected to periods of intense physiological strain, such as during major cardiac surgery. The evidence in this area is primarily comprised of systematic reviews and meta-analyses that combined data from numerous smaller-scale randomized controlled trials (RCTs).

These studies were observed in adult and pediatric patient populations undergoing procedures like bypass surgery. Researchers monitored several crucial outcomes monitoring physiological strain or stress, including short-term mortality following the procedure, the requirement for supportive medications to boost heart function (inotrope use), and the occurrence of major arrhythmias (irregular heartbeats).

Some research reports tracked lower measurements of required intraoperative inotropic support and fewer recorded instances of major arrhythmias in the observed populations. However, researchers have pointed out that the measured differences in these functional outcomes were described as small, and whether the evidence is sufficient to clarify the overall impact is a point of ongoing research. Furthermore, more recent, dedicated RCTs in high-risk surgery patients included observations of key injury markers (troponin I concentration) and reported similar measurements between the study groups.

Evidence for Use in Chronic Heart Failure

Research examined Фосфокреатин in research contexts involving outcomes related to systemic or functional imbalance in patients with established chronic heart failure (CHF). The research examined outcomes related to outcomes reflecting daily functioning or activity level and outcomes related to systemic or functional imbalance.

Long-Term Follow-up and Durability of Effect

Long-term effects are not fully established because the follow-up durations were limited in the clinical trials that were reviewed. Studies tracking outcomes beyond the immediate post-operative period or crisis phase are insufficient to draw conclusions about the sustained impact over extended time intervals.

The Research Landscape: What Remains Uncertain

The evidence highlights what is known — and what is still uncertain. A primary limitation is the modest size of the samples used in many of the individual RCTs that form the basis of the older meta-analyses. Furthermore, evidence quality varies across studies, and the findings were mixed for certain key physiological outcomes. This has led researchers to conclude that a large multicenter randomized trial is still critically needed to confirm the patterns observed in the smaller, combined studies.

Common questions about Фосфокреатин (FAQ)

Q: Is it safe for children to receive this treatment?

Official product information indicates that use of Фосфокреатин in children and adolescents is not established. This status reflects that sufficient clinical safety data is currently not available for this population group in regulatory documents.

Q: How long will I need to be on Фосфокреатин after my surgery?

This medication is given under an administration protocol that involves a distinct short-term regimen. Studies reviewed in the regulatory context had limited follow-up durations. This means that the sustained impact or benefit over extended periods (long-term effects) is not fully known.

Q: Does the drug have any warnings for people with diabetes or high blood pressure?

Regulatory documents do not list specific warnings for diabetes or high blood pressure (hypertension). However, official information does advise caution for patients with severe renal impairment or congestive heart failure. This is primarily due to the sodium and phosphate content of the parenteral solution. The product label also states that the risk of hypotension (low blood pressure) is explicitly linked to the rate of infusion.

How to Store and Dispose of Phosphocreatine

The storage and disposal of Phosphocreatine Disodium (powder for injection) must follow precise regulatory requirements to maintain its stability.

Storage Requirements

• Temperature and Light: The unreconstituted powder must be stored within a specific controlled temperature range (e.g., below 25 C or refrigerated 2 C to 8 C) and kept in the original carton to protect it from light.
• Handling: The product must not be frozen. It must be kept strictly out of the reach and sight of children.
• Stability: Once reconstituted into a solution, the product has a limited in-use stability (e.g., 24 hours). Any unused portion after this time must be discarded.

Disposal

Disposal of expired or unused medicine must not occur via household waste or wastewater. The product must be disposed of in accordance with local regulatory requirements for pharmaceutical waste, typically through an authorized collection point.